388 related articles for article (PubMed ID: 30019590)
21. Targeted Therapy of Colorectal Cancer.
Seeber A; Gastl G
Oncol Res Treat; 2016; 39(12):796-802. PubMed ID: 27889786
[TBL] [Abstract][Full Text] [Related]
22. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
Zaniboni A; Formica V
Cancer Chemother Pharmacol; 2016 Aug; 78(2):233-44. PubMed ID: 27091467
[TBL] [Abstract][Full Text] [Related]
23. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
[TBL] [Abstract][Full Text] [Related]
24. Systemic therapy for metastatic colorectal cancer.
Saltz L
J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):649-52. PubMed ID: 23704235
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
26. Colorectal Cancer: Why Does Side Matter?
Gallois C; Pernot S; Zaanan A; Taieb J
Drugs; 2018 Jun; 78(8):789-798. PubMed ID: 29790124
[TBL] [Abstract][Full Text] [Related]
27. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
30. Targeted therapy in advanced colorectal cancer: more data, more questions.
Ochenduszko SL; Krzemieniecki K
Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
[TBL] [Abstract][Full Text] [Related]
31. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
32. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
33. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
Hohla F; Winder T; Greil R; Rick FG; Block NL; Schally AV
World J Gastroenterol; 2014 May; 20(20):6102-12. PubMed ID: 24876732
[TBL] [Abstract][Full Text] [Related]
35. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
[TBL] [Abstract][Full Text] [Related]
38. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
Cremolini C; Morano F; Moretto R; Berenato R; Tamborini E; Perrone F; Rossini D; Gloghini A; Busico A; Zucchelli G; Baratelli C; Tamburini E; Tampellini M; Sensi E; Fucà G; Volpi C; Milione M; Di Maio M; Fontanini G; De Braud F; Falcone A; Pietrantonio F
Ann Oncol; 2017 Dec; 28(12):3009-3014. PubMed ID: 29045518
[TBL] [Abstract][Full Text] [Related]
39. First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study.
Beypinar I; Araz M; Uysal M; Yalcin S
J BUON; 2019; 24(1):68-76. PubMed ID: 30941953
[TBL] [Abstract][Full Text] [Related]
40. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]